Merck, the German health care and life sciences group, is tapping into China’s burgeoning biotech start-up community through a new grant program under which it is offering financial aid and broad technology support and hopes to help advance novel life-saving therapeutics.
SHANGHAI – To tap into China’s fast-growing biopharmaceutical sector and explore opportunities for bringing new drugs to market, Germany-based Merck KGAA is providing tailor made support to small emerging biotech companies through a grant program and will consider possible growth partnerships.
Committed to helping advance life-saving drugs to market, Merck’s first emerging biotech grant program started in 2014, awarding NGM...
Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.
Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
